An update on Pharma To Market’s response to COVID-19

Update 24 March 2020: All of our Australian & Malaysian-based team members are working from home.  No disruptions to our services are anticipated however some delays in dispatching materials via post or courier may be experienced. Office phone numbers have been redirected, so please continue to contact us via normal channels. Our team will be in touch if this is likely to affect your projects.

 Dear Valued Clients and Partners,

With Covid-19 happening around the world, we have all had to deal with the impact and uncertainty surrounding our communities and our businesses.  Our thoughts go out to everyone directly affected by the current situation.

For over 10 years, Pharma To Market has focused on our vision through our commitment to customer service, quality, and knowledge in our fields of expertise. With this vision in mind, we have implemented our business continuity plans to ensure continued service to our clients.

For many years, our team members have operated via encrypted access to our secure and robust remote environment, providing our teams with access to all business applications, web services and file servers on a platform certified against ISO 27001:2013 ‘Information Security Management System’.  We’ve implemented communication tools and have assessed and tested home office infrastructure for all personnel in order to avoid any major disruptions to our operations in the event that our people need to work from home. We are fully equipped and prepared to maintain business as usual services across our regional business with these IT setups.

Following the guidance of World Health Organization, as well as directives from local governments, we are assessing the situation on a daily basis and as necessary will allow employees to work remotely. In addition, all business travel has been temporarily suspended.

Currently, we are operating as per normal across all our countries and will continue delivering our services to you with minimal disruption.

We have put these measures in place to ensure the health and safety of our people and their families, as well as to minimize any impact to our services, so that you continue to receive the quality and support that we know you have always counted on Pharma To Market to deliver.

Our leadership team will continue to closely monitor, assess and adapt to any changing circumstances.

From all of us at Pharma To Market, we hope you stay safe and healthy, and please do not hesitate to contact us if you have any concerns.


Nick, Johanna and Joelle

Co-Directors of Pharma To Market


Pharma To Market look forward to catching up with our colleagues at ARCS ASC in Sydney

Pharma To Market look forward to catching up with our colleagues at ARCS ASC in Sydney

We are pleased to bring their six members of our team to the annual ARCS Annual Scientific Conference in Sydney this month. Joelle Chia, Pharma To Market’s Director of their South-East Asian operations will be speaking about regulatory affairs requirements in ASEAN and Daria Wain, Pharma To Market’s Regulatory Publishing Specialist will be speaking about tips to streamline your eSubmission processes. Congratulations to our colleagues at ARCS for pulling together an excellent program. We look forward to catching up with all of our colleagues from across Australia at what promises to be a fantastic conference.


Join us at our first Asia regulatory & pharmacovigilance workshop

Pharma To Market looks forward to hosting you at our first-ever Pharmaceutical Regulatory Affairs & Pharmacovigilance Asia Workshop, happening on the 26th October 2018 in Singapore. This workshop is co-organised together with the Pharmaceutical Society of Singapore.

Do join us for a full-day workshop specially curated to provide participants in the pharmaceutical industry with key regulatory and pharmacovigilance knowledge and actionable insights. Our goal is to bring together industry experts to give talks that are strategy- or implementation-focused so that participants can bring back ideas to help them navigate the complex and ever-changing regulations in the region. The event also aims to provide a networking avenue for regulatory and pharmacovigilance professionals in the region to exchange approaches to current challenges.

Guest speakers from MSD, Novartis, Roche and Sanofi, as well as trainers from Pharma To Market’s Australian office will discuss these topics in the workshop:
• Innovative approaches to deliver regulatory process optimisation in pharma companies
• Overview of regulatory CMC requirements for pharmaceuticals
• Strategic pharmacovigilance literature surveillance Asian hub
• Key risk minimization regulations and their impact on countries in the region
• Fundamentals on pharmacovigilance inspection readiness in Asia
• Lifecycle management – from manufacturing shop-floor to the registered dossier


RAPS Regulatory Convergence

Pharma To Market are pleased to be exhibiting at and attending the RAPS Regulatory Convergence 2016 on 17-20 September 2016 in California, USA.

We are looking forward to meeting our fellow delegates from the USA and around the globe to explore how Pharma To Market can assist companies looking to enter the Australian and other emerging markets.

The congress is a great opportunity to learn more about global healthcare regulations and exchange ideas with key industry leaders.

If you would like to meet with us at the congress to learn how Pharma To Market can help shape your success story, contact